⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9158077 | 0.87 | TAAR1 (0.43) | — | |
| SCHEMBL15304176 | 0.85 | RAB9A (0.58) | — | |
| SCHEMBL9158239 | 0.83 | CYP2A6 (0.47) | — | |
| SCHEMBL9156751 | 0.83 | CYP2A6 (0.47) | — | |
| SCHEMBL9154340 | 0.82 | NPC1 (0.40) | — | |
| SCHEMBL10282267 | 0.82 | SMN1; SMN2 (0.49) | — | |
| SCHEMBL9156125 | 0.79 | SMN1; SMN2 (0.46) | — | |
| SCHEMBL9153748 | 0.78 | GRM5 (0.50) | — | |
| SCHEMBL771164 | 0.78 | — | — | |
| SCHEMBL10721748 | 0.77 | RAB9A (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492210-B2 | Tricyclic compounds and their use | HUTCHISON MEDIPHARMA LIMITED (CN) | 2025-12-09 | — | — | US | disclosed |
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| WO-2024094731-A1 | NOVEL COMPOUNDS FOR THE DIAGNOSIS OF TDP-43 PROTEINOPATHIES | AC IMMUNE SA (CH) | 2024-05-10 | — | — | WO | disclosed |
| CN-117486888-A | Tricyclic compounds and uses thereof | 和记黄埔医药（上海）有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-117486890-A | Tricyclic compounds and uses thereof | 和记黄埔医药（上海）有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-113966336-B | Tricyclic compounds and uses thereof | 和记黄埔医药（上海）有限公司 | 2023-11-07 | — | — | CN | disclosed |
| EP-3784669-B1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMA (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230331676-A1 | NAPHTHYLUREA COMPOUND, METHODS OF PREPARATION AND USE THEREOF | HENAN RADIOMEDICAL SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230331676-A1 | NAPHTHYLUREA COMPOUND, METHODS OF PREPARATION AND USE THEREOF | HENAN RADIOMEDICAL SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20070225229-A1 | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2007-09-27 | — | — | US | disclosed |
| US-20070225229-A1 | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2007-09-27 | — | — | US | disclosed |
| US-20070225229-A1 | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2007-09-27 | — | — | US | disclosed |
| US-7268153-B2 | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators | MERCK & CO., INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-7268153-B2 | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators | MERCK & CO., INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-7268153-B2 | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators | MERCK & CO., INC. (US) | 2007-09-11 | — | — | US | disclosed |
| EP-1755572-A2 | N- (2-BENZYL) -2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005120477-A2 | N- (2-BENZYL) -2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20050277681-A1 | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2005-12-15 | — | — | US | disclosed |
| EP-0445248-A1 | PYRIDINE DERIVATIVES. | MERCK PATENT GMBH (DE) | 1991-09-11 | — | — | EP | disclosed |